CADPS Antikörper (N-Term)

Produktnummer ABIN499525

Dieses Kaninchen Polyklonal-Antikörper erkennt spezifisch CADPS in WB, IHC (p) und EIA. Er zeigt eine Reaktivität gegenüber Human, Maus und Ratte.

Kurzübersicht für CADPS Antikörper (N-Term) (ABIN499525)

Target: CADPS (Ca++-Dependent Secretion Activator (CADPS))

Reaktivität: Human, Maus, Ratte

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser CADPS Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Enzyme Immunoassay (EIA)

Produktdetails anti-CADPS Antikörper

Bindungsspezifität: N-Term

Spezifität: This antibody reacts to CAPS1.

Aufreinigung: Affinity chromatography purified via peptide column

Immunogen: CAPS1 antibody was raised against a 21 amino acid peptide near the amino terminus of the human CAPS1.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: ELISA. Western Blot: CAPS1 antibody can be used for detection of CAPS1 by Western blot at 0.25 -0.5 μg/mL. Immunohistochemistry.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: PBS containing 0.02 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: Store the antibody undiluted at 2-8 °C.

Details zu CADPS

Target: CADPS (Ca++-Dependent Secretion Activator (CADPS))

Andere Bezeichnung: CADPS

Hintergrund: CAPS1 and its related protein CAPS2 encode novel neural/endocrine-specific cytosolic and peripheral membrane proteins. Both are essential components of the synaptic vesicle priming machinery and are required for the Ca2+-regulated exocytosis of secretory vesicles, CAPS-deficienct neurons contain no or very few fusion competent synaptic vesicles, causing a selective impairment of fast phasic transmitter release. CAPS1 acts at a stage in exocytosis that follows ATP-dependent priming, which involves the essential synthesis of phosphatidylinositol 4,5-bisphosphate and is thought to be a specific regulator of large dense-core vesicle fusion. Numerous isoforms of CAPS1 are known to exist. This CAPS1 antibody is predicted to be specific to CAPS1 and not recognize CAPS2.Synonyms: CAPS, CAPS-1, CAPS1, Calcium-dependent activator protein for secretion 1, Calcium-dependent secretion activator 1, KIAA1121

Gen-ID: 8618

NCBI Accession: NP_899631

UniProt: Q9ULU8

Pathways: Synaptic Vesicle Exocytosis